Shanghai Allist Shares Drop to Limit After Clinical Trial Disappointment

Shanghai Allist Pharmaceuticals shares fell 20% to the daily limit of 89.26 yuan on Thursday. This decline followed the failure of a Phase 3 clinical trial for the lung cancer drug firmonertinib. The drop reflects investor concern regarding the drug's commercial prospects after U.S. partner ArriVent Biopharma reported that the treatment did not meet its primary clinical goals.

The Phase 3 FURVENT trial evaluated firmonertinib for patients with non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations. The study aimed to demonstrate an improvement in progression-free survival (PFS) compared to standard chemotherapy, but the drug failed to reach this benchmark.

Trial Data and Statistical Significance

Clinical trials in oncology measure efficacy through the primary endpoint of progression-free survival. This metric tracks the length of time during and after treatment that a patient lives with the disease without it worsening. In the FURVENT trial, the 240 mg dose of firmonertinib resulted in a median progression-free survival of 11 months, compared to 9.5 months for the chemotherapy control arm.

Although the drug showed a numerical improvement, the result lacked the statistical rigor required for regulatory approval. The study reported a p-value of 0.0654. In clinical research, a p-value of less than 0.05 is the standard threshold for establishing statistical significance, which indicates the result is unlikely to have occurred by random chance.

Impact on Regulatory and Market Outlook

For pharmaceutical developers, missing the p-value threshold in a Phase 3 trial often necessitates additional studies or risks rejection by regulatory bodies like the U.S. Food and Drug Administration. The failure of the FURVENT trial is a setback for ArriVent Biopharma, which licensed the drug from Shanghai Allist to pursue global markets outside of China.

Shanghai Allist maintains the rights to the drug within China. The company now faces a cooling of investor sentiment as the market reevaluates the global commercialization timeline for the asset. The 20% single-day decline to the 89.26 yuan limit reflects the immediate repricing of the company’s growth expectations tied to the international expansion of its oncology pipeline.